Benzinga·2026-01-02 13:58Group 1: Market Overview - As of January 2, 2026, two stocks in the health care sector are signaling potential warnings for momentum-focused investors [1] - The Relative Strength Index (RSI) is a key momentum indicator that helps traders assess stock performance by comparing price strength on up days versus down days [2] Group 2: Company Analysis - Teva Pharmaceutical Industries Ltd - Teva Pharmaceutical's long-term issuer credit rating was upgraded by S&P Global Ratings from 'BB' to 'BB+' with a stable outlook [6] - Teva's stock has increased approximately 16% over the past month, reaching a 52-week high of $31.99 [6] - The current RSI value for Teva is 71.6, indicating it may be overbought [6] - Teva's shares closed at $31.21, reflecting a slight decline of 0.4% [6] - Teva has a momentum score of 92.72 and a value score of 27.43 [6] Group 3: Company Analysis - Exact Sciences Corp - Exact Sciences was involved in a significant acquisition by Abbott Laboratories, which agreed to purchase the company for $105 per common share, totaling an equity value of approximately $21 billion [6] - Exact Sciences' stock has gained around 7% over the past month, with a 52-week high of $102.00 [6] - The RSI value for Exact Sciences is 77.8, suggesting it is also potentially overbought [6] - Exact Sciences' shares closed at $101.56, down 0.3% [6]